We are live on ! Find out more
CNCR

ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR

Delisted

CNCR was delisted on the 27th of May, 2025.

Back to rankings

0 hedge funds and large institutions have $0 invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2025 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.02% less ownership

Funds ownership: 0.02% → 0% (-0.02%)

100% less funds holding

Funds holding: 1 → 0 (-1)

100% less capital invested

Capital invested by funds: $2.24K → $0 (-$2.24K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
–
Holders Change
-1
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Osaic Holdings
Osaic Holdings
Arizona
-$2.24K
Name Holding Trade Value Shares
Change 		Change in
Stake
Osaic Holdings
1
Osaic Holdings
Arizona
– -$2.24K -150 Closed

CNCR Hedge Fund Activity: Q3 2025 in Review

0 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q3 2025, worth a combined $0 — down 100% from $2.24K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of CNCR and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest seller was Osaic Holdings, exiting entirely with an estimated $2.24K sold.

  • 0 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q3 2025, down from 1 in Q2 2025.
  • Funds reported $0 of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q3 2025, down 100% quarter-over-quarter.
  • 0 funds opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q3 2025 and 1 closed out, a net change of -1 holder.
  • The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q3 2025 was Osaic Holdings, an estimated $2.24K sold.

Based on aggregated 13F filings for Q3 2025.